HRP20110724T1 - Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba - Google Patents
Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba Download PDFInfo
- Publication number
- HRP20110724T1 HRP20110724T1 HR20110724T HRP20110724T HRP20110724T1 HR P20110724 T1 HRP20110724 T1 HR P20110724T1 HR 20110724 T HR20110724 T HR 20110724T HR P20110724 T HRP20110724 T HR P20110724T HR P20110724 T1 HRP20110724 T1 HR P20110724T1
- Authority
- HR
- Croatia
- Prior art keywords
- mbp
- basic protein
- myelin basic
- treatment
- multiple sclerosis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 12
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 title claims abstract 5
- 102000047918 Myelin Basic Human genes 0.000 title claims abstract 5
- 101710107068 Myelin basic protein Proteins 0.000 title claims abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 5
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 5
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108010080451 HLA-DQ6 antigen Proteins 0.000 claims 1
- 108010051539 HLA-DR2 Antigen Proteins 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Confectionery (AREA)
Abstract
Smjesa koja sadrži sljedeće peptide mijelinskog bazičnog proteina: MBP 30-44; MBP 83-99; MBP 131-145; iMBP 140-154. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Smjesa koja sadrži sljedeće peptide mijelinskog bazičnog proteina:
MBP 30-44;
MBP 83-99;
MBP 131-145; i
MBP 140-154.
2. Smjesa prema zahtjevu 1 koja se u biti sastoji od sljedećih peptida mijelinskog bazičnog proteina:
MBP 30-44;
MBP 83-99;
MBP 131-145; i
MBP 140-154.
3. Smjesa prema zahtjevu 1 ili 2 za uporabu u liječenju ili prevenciji bolesti.
4. Smjesa prema zahtjevu 1 ili 2 za uporabu u liječenju ili prevenciji multiple skleroze.
5. Smjesa prema zahtjevu 1 ili 2 za uporabu u liječenju ili prevenciji optičkog neuritisa koji je povezan s multiplom sklerozom.
6. Uporaba smjese prema zahtjevu 1 ili 2 u proizvodnji lijeka za liječenje multiple skleroze.
7. Uporaba smjese prema zahtjevu 1 ili 2 u proizvodnji lijeka za liječenje optičkog neuritisa koji je povezan s multiplom sklerozom.
8. Smjesa za uporabu prema zahtjevu 3 ili 4 za primjenu nakon protokola postupnog povećavanja doze.
9. Smjesa za uporabu prema zahtjevu 3 ili 4 za primjenu subjektu koji je pozitivan na HLA-DQ6 ili HLA-DR2.
10. Kit koji sadrži sljedeće peptide mijelinskog bazičnog proteina:
MBP 30-44;
MBP 83-99;
MBP 131-145; i
MBP 140-154
za istodobnu, odvojenu ili uzastopnu primjenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0721430A GB0721430D0 (en) | 2007-10-31 | 2007-10-31 | Composition |
| GB0800962A GB0800962D0 (en) | 2008-01-18 | 2008-01-18 | Conposition |
| PCT/GB2008/003673 WO2009056833A2 (en) | 2007-10-31 | 2008-10-30 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110724T1 true HRP20110724T1 (hr) | 2011-12-31 |
Family
ID=40591554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110724T HRP20110724T1 (hr) | 2007-10-31 | 2011-10-06 | Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8623827B2 (hr) |
| EP (1) | EP2211892B1 (hr) |
| JP (1) | JP5361895B2 (hr) |
| KR (1) | KR101570383B1 (hr) |
| CN (1) | CN101848725B (hr) |
| AT (1) | ATE518546T1 (hr) |
| AU (1) | AU2008320657B2 (hr) |
| BR (1) | BRPI0818302B1 (hr) |
| CA (1) | CA2703170C (hr) |
| CY (1) | CY1112620T1 (hr) |
| DK (1) | DK2211892T3 (hr) |
| EA (1) | EA017999B1 (hr) |
| EC (1) | ECSP10010211A (hr) |
| HK (1) | HK1142803A1 (hr) |
| HR (1) | HRP20110724T1 (hr) |
| IL (1) | IL204662A (hr) |
| MX (1) | MX2010004698A (hr) |
| MY (1) | MY158800A (hr) |
| NZ (1) | NZ583924A (hr) |
| PL (1) | PL2211892T3 (hr) |
| PT (1) | PT2211892E (hr) |
| SI (1) | SI2211892T1 (hr) |
| WO (1) | WO2009056833A2 (hr) |
| ZA (1) | ZA201001748B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230233B1 (hu) | 2000-08-21 | 2015-10-28 | Apitope Technology (Bristol) Limited | Peptid szelekciós módszer |
| PT2211892E (pt) | 2007-10-31 | 2011-10-18 | Apitope Technology Bristol Ltd | Composições compreendendo péptidos de proteína básica de mielina e suas utilizações médicas |
| ES2566230T3 (es) * | 2009-10-12 | 2016-04-11 | Lifebio Laboratories Llc | Composición para el tratamiento de la esclerosis múltiple |
| GB201300684D0 (en) * | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| GB201603582D0 (en) * | 2016-03-01 | 2016-04-13 | Apitope Int Nv | Peptides |
| GB201700095D0 (en) * | 2017-01-04 | 2017-02-22 | Apitope Int Nv | Composition |
| AU2018206356A1 (en) * | 2017-01-04 | 2019-07-18 | Worg Pharmaceuticals (Zhejiang) Co., Ltd. | Therapeutic method using tolerogenic peptides |
| CA3072867A1 (en) * | 2017-08-14 | 2019-02-21 | Apitope Technology (Bristol) Limited | Method |
| WO2022221622A1 (en) | 2021-04-16 | 2022-10-20 | Cour Pharmaceuticals Development Company Inc. | Method of tracking maintenance of immunological tolerance |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5817629A (en) * | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| HU230233B1 (hu) * | 2000-08-21 | 2015-10-28 | Apitope Technology (Bristol) Limited | Peptid szelekciós módszer |
| US20040096456A1 (en) | 2000-12-01 | 2004-05-20 | Conti-Fine Bianca M | Method to treat hemophilia |
| GB0202399D0 (en) * | 2002-02-01 | 2002-03-20 | Univ Bristol | Peptide |
| PT2211892E (pt) | 2007-10-31 | 2011-10-18 | Apitope Technology Bristol Ltd | Composições compreendendo péptidos de proteína básica de mielina e suas utilizações médicas |
-
2008
- 2008-10-30 PT PT08844568T patent/PT2211892E/pt unknown
- 2008-10-30 PL PL08844568T patent/PL2211892T3/pl unknown
- 2008-10-30 NZ NZ583924A patent/NZ583924A/en unknown
- 2008-10-30 WO PCT/GB2008/003673 patent/WO2009056833A2/en active Application Filing
- 2008-10-30 JP JP2010530555A patent/JP5361895B2/ja active Active
- 2008-10-30 CN CN2008801138365A patent/CN101848725B/zh active Active
- 2008-10-30 AT AT08844568T patent/ATE518546T1/de active
- 2008-10-30 EP EP08844568A patent/EP2211892B1/en active Active
- 2008-10-30 DK DK08844568.9T patent/DK2211892T3/da active
- 2008-10-30 BR BRPI0818302-3A patent/BRPI0818302B1/pt active IP Right Grant
- 2008-10-30 AU AU2008320657A patent/AU2008320657B2/en active Active
- 2008-10-30 US US12/740,976 patent/US8623827B2/en active Active
- 2008-10-30 KR KR1020107005853A patent/KR101570383B1/ko active IP Right Grant
- 2008-10-30 EA EA201070541A patent/EA017999B1/ru not_active IP Right Cessation
- 2008-10-30 MX MX2010004698A patent/MX2010004698A/es active IP Right Grant
- 2008-10-30 SI SI200830411T patent/SI2211892T1/sl unknown
- 2008-10-30 CA CA2703170A patent/CA2703170C/en active Active
- 2008-10-30 MY MYPI2010001917A patent/MY158800A/en unknown
-
2010
- 2010-03-11 ZA ZA2010/01748A patent/ZA201001748B/en unknown
- 2010-03-22 IL IL204662A patent/IL204662A/en active IP Right Grant
- 2010-05-28 EC EC2010010211A patent/ECSP10010211A/es unknown
- 2010-09-27 HK HK10109209.6A patent/HK1142803A1/xx unknown
-
2011
- 2011-10-06 HR HR20110724T patent/HRP20110724T1/hr unknown
- 2011-10-25 CY CY20111101006T patent/CY1112620T1/el unknown
-
2013
- 2013-12-06 US US14/099,463 patent/US9381234B2/en active Active
-
2016
- 2016-06-03 US US15/173,018 patent/US9775880B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110724T1 (hr) | Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba | |
| MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| BRPI0607326A2 (pt) | composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento | |
| WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
| MY171300A (en) | Pharmaceutical composition | |
| BRPI0416796A (pt) | compostos orgánicos | |
| BR112015010477A2 (pt) | combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| EA201001577A1 (ru) | Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения | |
| UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
| SG166125A1 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease | |
| ATE530544T1 (de) | Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| BR112013031652A2 (pt) | métodos de tratamento para doenças retinais | |
| EA200702522A1 (ru) | Система доставки лекарств в полость рта и способы ее применения | |
| GB0620385D0 (en) | Novel compounds | |
| JP2011500776A5 (hr) | ||
| BR102013003570A8 (pt) | Composições de plasma rico em plaquetas | |
| DE60218193D1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| RU2012157328A (ru) | Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера | |
| CL2021000160A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| BRPI0720230B8 (pt) | formulação nutricional oralmente administrável, uso da formulação, e, composição | |
| AR117614A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением |